Cancer's genetic heterogeneity necessitates a move beyond traditional, one-size-fits-all treatments towards personalized medicine.  Advances in genomics have profoundly impacted our understanding of the disease's genetic basis, revealing driver mutations and specific pathways involved in oncogenesis.  Next-generation sequencing technologies allow for comprehensive genomic profiling of tumour samples, identifying unique mutational signatures and informing targeted therapies. This includes the development of therapies like tyrosine kinase inhibitors against specific mutations (e.g., EGFR mutations in lung cancer) and immune checkpoint inhibitors that leverage the patient's own immune system to combat cancer cells displaying specific neoantigens.

Practical applications of these advancements include pre-emptive screening for individuals with high genetic risk, utilizing genetic information to predict treatment response and recurrence, and the development of novel therapeutic strategies tailored to specific genetic alterations.  However, challenges remain, including the high cost of genomic sequencing, the complexity of interpreting vast genomic data, and the need for robust clinical trials to validate personalized approaches.  Despite these hurdles, the integration of genomic information into cancer care is rapidly progressing, paving the way for more effective and less toxic therapies, ultimately improving patient outcomes.